

In re Application of: Scott, et al.)
Serial No: 10/817,423)
Filed: April 2, 2004)
Confirmation No: 1563)
Title: Novel Immunotherapy)

Group Art Unit: 1644
Examiner: M. Haddad
Our Client ID: 22827
Our Account No: 04-1403

RESPONSE AND PRELIMINARY AMENDMENT

This is a response/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is to be treated as the signature to the attachment in absence of a signature thereto.

Fee requirements (if any) have been calculated as shown below:

Claims remaining after amendment	Highest number previously paid for	Present Extra	Additional Fee
Total Effective Claims 21 minus 42 = 0		X \$50 =	\$.00
Independent Claims 2 minus 5 = 0		x \$200 =	\$.00
If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time, add \$290.00 (per application)			\$.00
Since Official Action set an <u>original</u> due date of <u>February 10, 2005</u> , PETITION is hereby made for an extension to cover the date this response is filed for which the requisite fee is enclosed (1 month \$120; 2 months \$450; 3 months \$1020; 4 months \$1590, 5 months \$2,160)			\$.00
If Terminal Disclaimer enclosed, add Rule 20(d) Official Fee (\$110.00)			\$.00
SUBTOTAL:			\$.00
If "small entity" verified statement filed [] previously, [] herewith, enter one-half (1/2) of subtotal and <u>subtract</u>			\$.00
TOTAL:			\$.00
Other: _____			\$.00
TOTAL FEE ENCLOSED:			\$.00

The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any fees in addition to the fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (deficiency only) now or hereafter relative to this application and the resulting official document under Rule 20, or credit any overpayment, to our Account No. shown in the heading hereof for which purpose a duplicate copy of this sheet is attached. This statement does not authorize charge of the issue fee in this case.

ADDRESS:
Post Office Box 1449
Greenville, SC 29602 USA
Customer ID No.: 22827
Telephone: 864-271-1592
Facsimile: 864-233-7342

DORITY & MANNING
ATTORNEYS AT LAW, P.A.

By: Christina L. Mangelsen, Patent Agent Reg. No: 50,244 Date: 02/01/2005

Signature: *Christina L. Mangelsen*

I hereby certify that this correspondence and any referenced attachment and fee are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, Post Office Box 1450, Alexandria, VA 22313-1450, on February 1, 2005.

Sandra S. Perkins

(Typed or printed name of person mailing paper or fee)

Sandra S. Perkins
(Signature of person mailing paper or fee)

ATTORNEY DOCKET NO: CXU-407

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Scott, et al.

) Examiner: M. Haddad

Serial No: 10/817,423

) Art Unit: 1644

Filed: April 2, 2004

) Confirmation No: 1563

For: Novel Immunotherapy

) Deposit Account No: 04-1403

) Customer No: 22827

**RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY
AMENDMENT**

Honorable Commissioner of Patents and Trademarks
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement dated January 10, 2005, and prior to action on the merits please find attached hereto:

Amendments to the Claims beginning on page 2 of this paper, and

Remarks, beginning on page 5 of this paper.